Form SC 13G/A INTERCEPT PHARMACEUTICAL Filed by: AMERIPRISE FINANCIAL INC
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Intercept (ICPT) NASH Trial Amendment Doesn't Change Probability of Success - Cantor Fitzgerald
February 10, 2017 12:39 PM ESTCantor Fitzgerald analyst Elemer Piros doesn't have much nice to say about Intercept Pharmaceuticals (NASDAQ: ICPT) REGENERATE trial change. The firm maintained an Underweight rating and price target of $60.
The analyst does not see a change to their probability of success... More
Intercept Pharmaceuticals (ICPT) Trial Amendments 'Increase Probability for Success' - Wedbush
February 10, 2017 12:31 PM ESTWedbush analyst Liana Moussatos reiterated her Outperform rating and $224 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after protocol amendments to the Phase 3 REGENERATE trial, which she said er the bar for success, while retaining significant upside.
Moussatos commented, "Intercept announced two protocol amendments to... More
